2020-2027 Analysis and Review Fibrinogen Market

Fibrinogen Market

Fibrinogen Market by Clinical Application (Congenital Fibrinogen Deficiency, Coagulopathic Bleeding) by End Users (Hospital & Clinics, Ambulatory Surgical Centers and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 – 2027

23-05-2020 REP-HC-5094 40 Tables 120 pages Format

The fibrinogen market was valued at USD 1,645.2 Mn by 2019. The growing incidence of congenital fibrinogen deficiency worldwide primarily drives the fibrinogen market growth. Technological advancement in the recombinant DNA technology for the development of fibrinogen to treat bleeding complications in patients under medical supervision will further accentuate the fibrinogen market.

Fibrinogen Market

Fibrinogen is a glycoprotein complex which is synthesized by the liver and circulates in the blood of the vertebrates. In bleeding episodes it is enzymatically converted by thrombin into fibrin and then finally a blood clot that prevents bleeding. It is also considered as an acute-phase protein that achieves elevated blood levels in conditions of tissue injury, systemic inflammation, etc. It needs to be taken under medical supervision in order to prevent the occurrence of side effects such as numbness, severe headache, sweating, coughing up blood, etc.

The major segments related to the fibrinogen market are: 

By Clinical Application (2017–2027; US$ Mn)

Congenital Fibrinogen Deficiency

Coagulopathic Bleeding

By End Users (2017–2027; US$ Mn)

Hospital & Clinics

Ambulatory Surgical Centers

Others

Geography Segment (2017–2027; US$ Mn)

North America

U.S.
Canada

Europe

United Kingdom
Germany
Russia
France
Italy
Spain
Ukraine
Rest of Europe

Asia Pacific

China
Japan
Rest of Asia Pacific

Latin America (LATAM)

Brazil
Mexico
Rest of Latin America

Middle East and Africa (MEA)

GCC
Rest of MEA
 

Justification for study?

  • The intention of the study is to give a comprehensive outlook of the global fibrinogen market
  • The overall segmentation of the fibrinogen market, by clinical application, end-users and geography are minutely studied. Congenital fibrinogen deficiency and hospital & clinics are dominating the clinical application and end-user segments respectively
  • Rising prevalence of congenital fibrinogen deficiency worldwide
  • Significant increase in the number of patients suffering from coagulopathy bleeding will further accentuate the fibrinogen market growth

Report gist?

  • The study of the global fibrinogen market includes qualitative analysis of factors such as drivers, restraints, and opportunities
  • The report covers a qualitative and quantitative analysis of the overall market segmented on the basis of clinical application and end-users and categorization of the same at geography level
  • This research report presents the analysis of each segment from 2017 to 2027 in which 2019 is considered as the base year. The compounded annual growth rate is calculated for the respective segments from 2020 to 2027
  • The study includes the profiles of major market players with a significant global and regional presence along with top company positioning 

Significant customers?

  • This study is suitable for industry participants and stakeholders in the biopharmaceutical industry actively engaged in the production and marketing of fibrinogen due to the  rising prevalence of congenital fibrinogen deficiency throughout the globe
  • The report will benefit researchers engaged in the development of fibrinogen for addressing the issues with coagulopathy bleeding
  • Managers with financial institutions looking to publish recent and forecasted statistics pertaining to fibrinogen market
  • Financial institutions, venture capitalist, analysts, investors, government organizations, policymakers, regulatory authorities, researchers, looking for insights into the market to determine future strategies 

Segment Analysis

Congenital fibrinogen deficiency is presently dominating the clinical application segment for the fibrinogen market. According to the latest statistics provided by the Orphanet Journal of Rare Diseases the global prevalence rate of congenital fibrinogen deficiency is 1-9 per 1 00,0000 individuals worldwide. Further clinical studies state that if occurs across all age groups having the same incidence rate in both the sexes. Coagulopathic bleeding is going to register excellent market growth during the forecast period, due to the significant increase in the number of diabetic patients suffering from bleeding diathesis during the dental procedures. Genetic disorders such as hemophilia and Von Willebrand disease can significantly reduce the clotting factors in human blood.

Hospitals & clinics are currently leading the end-user segment for the fibrinogen market. A constant rise in surgical procedures worldwide has led to an increasing demand for fibrinogen to prevent any incidents of internal bleedings of visceral organs. Ambulatory surgical centers are expected to register impressive market growth in the near future on account of its ability to provide medical aid to people suffering from fatal vehicle accidents on highways, fibrinogen is utilized widely to prevent profuse bleeding due to deep tissue lacerations and cuts and stabilize the patient's health.

North America is presently spearheading the geography segment for the fibrinogen market. As per the latest research citings presented by the Center for Disease Control and Prevention (CDC), in the United States afibrinogenemia accounts for 24% of all inherited abnormalities of fibrinogen. The affordable reimbursement scenario for fibrinogen formulations further bolsters the market growth. The supportive regulatory environment provided by the USFDA for expediting the clearance procedure for fibrinogen products for its use in treating acute bleeding episodes in human beings further accentuates the market growth in the region. Europe is the second-largest regional segment for the fibrinogen market. Strategic collaboration between the Biopharmaceutical companies and academic research institutes for developing fibrinogen by harnessing the recombinant DNA technology primarily drives the market growth in the region. The Asia Pacific is anticipated to be the fastest-growing regional segment for the fibrinogen market. Significant increase in occupational hazards causing coagulopathy bleedings and constant rise in the medical tourism industry further fortify the market growth in the Asia Pacific region.

Select License Type

$4,600
$6,600
$9,500

Safe and Secure SSL Encrypted

Have a Question?

We will help you find what you are looking for.

Call 1-518-730-1560

Contact sales

How can we help you?

Get in touch with us or find an office closest to you.